Friedman Daniel J, Olivas-Martinez Antonio, Dalgaard Frederik, Fudim Marat, Abraham William T, Cleland John G F, Curtis Anne B, Gold Michael R, Kutyifa Valentina, Linde Cecilia, Tang Anthony S, Ali-Ahmed Fatima, Inoue Lurdes Y T, Sanders Gillian D, Al-Khatib Sana M
Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Department of Biostatistics, University of Washington, Seattle, Washington.
Heart Rhythm. 2024 Jun;21(6):845-854. doi: 10.1016/j.hrthm.2024.01.058. Epub 2024 Feb 14.
Women might benefit more than men from cardiac resynchronization therapy (CRT) and do so at shorter QRS durations.
This meta-analysis was performed to determine whether sex-based differences in CRT effects are better accounted for by height, body surface area (BSA), or left ventricular end-diastolic dimension (LVEDD).
We analyzed patient-level data from CRT trials (MIRACLE, MIRACLE ICD, MIRACLE ICD II, REVERSE, RAFT, COMPANION, and MADIT-CRT) using bayesian hierarchical Weibull regression models. Relationships between QRS duration and CRT effects were examined overall and in sex-stratified cohorts; additional analyses indexed QRS duration by height, BSA, or LVEDD. End points were heart failure hospitalization (HFH) or death and all-cause mortality.
Compared with men (n = 5628), women (n = 1439) were shorter (1.62 [interquartile range, 1.57-1.65] m vs 1.75 [1.70-1.80] m; P < .001), with smaller BSAs (1.76 [1.62-1.90] m vs 2.02 [1.89-2.16] m; P < .001). In adjusted sex-stratified analyses, the reduction in HFH or death was greater for women (hazard ratio, 0.54; credible interval, 0.42-0.70) than for men (hazard ratio, 0.77; credible interval, 0.66-0.89; P = .009); results were similar for all-cause mortality even after adjustment for height, BSA, and LVEDD. Sex-specific differences were observed only in nonischemic cardiomyopathy. The effect of CRT on HFH or death was observed at a shorter QRS duration for women (126 ms) than for men (145 ms). Indexing QRS duration by height, BSA, or LVEDD attenuated sex-specific QRS duration thresholds for the effects of CRT on HFH or death but not on mortality.
Although body size partially explains sex-specific QRS duration thresholds for CRT benefit, it is not associated with the magnitude of CRT benefit. Indexing QRS duration for body size might improve selection of patients for CRT, particularly with a "borderline" QRS duration.
女性可能比男性从心脏再同步治疗(CRT)中获益更多,且在更短的QRS波时限时就能获益。
进行此项荟萃分析以确定CRT疗效的性别差异是否能更好地通过身高、体表面积(BSA)或左心室舒张末期内径(LVEDD)来解释。
我们使用贝叶斯分层威布尔回归模型分析了CRT试验(MIRACLE、MIRACLE ICD、MIRACLE ICD II、REVERSE、RAFT、COMPANION和MADIT-CRT)的患者水平数据。总体上以及在按性别分层的队列中检查了QRS波时限与CRT疗效之间的关系;另外的分析按身高、BSA或LVEDD对QRS波时限进行了指数化。终点为心力衰竭住院(HFH)或死亡以及全因死亡率。
与男性(n = 5628)相比,女性(n = 1439)更矮(1.62[四分位间距,1.57 - 1.65]米对1.75[1.70 - 1.80]米;P < 0.001),体表面积更小(1.76[1.62 - 1.90]平方米对2.02[1.89 - 2.16]平方米;P < 0.001)。在调整后的按性别分层分析中,女性HFH或死亡的降低幅度(风险比,0.54;可信区间,0.42 - 0.70)大于男性(风险比,0.77;可信区间,0.66 - 0.89;P = 0.009);即使在对身高、BSA和LVEDD进行调整后,全因死亡率的结果也相似。仅在非缺血性心肌病中观察到了性别特异性差异。CRT对HFH或死亡的疗效在女性(126毫秒)比男性(145毫秒)更短的QRS波时限时就已观察到。按身高、BSA或LVEDD对QRS波时限进行指数化减弱了CRT对HFH或死亡疗效的性别特异性QRS波时限阈值,但对死亡率没有影响。
尽管体型部分解释了CRT获益的性别特异性QRS波时限阈值,但它与CRT获益的程度无关。按体型对QRS波时限进行指数化可能会改善CRT患者的选择,尤其是对于“临界”QRS波时限的患者。